Stock Ratings / Health Care / GTBP / earnings

CLRB (37) TVRD (40) ASBP (33) CALC (47) ⌘ Pro Terminal →

GT Biopharma Inc. (GTBP) Next Earnings Date & Expected ±12.5% Move

$5.60 +1.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

GT Biopharma Inc. (GTBP) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $11.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GTBP)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.70 Expected Swing

MODEL EARNINGS SETUP GAUGE

GTBP Quantitative Pre-Earnings Setup: 46/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (46/100)Model Risk Weight (54/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$28.4M	-$12.9M	52%
FY 2024	2024-12-31	$0	-$13.2M	-$12.9M	52%
FY 2023	2023-12-31	$0	-$7.6M	-$8.9M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GTBP)

✓Walkthrough of GTBP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GTBP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.27%▼ DESCENDING CHANNEL

2026-10-30O $5.47H $5.60L $5.30C $5.60VOL 20.2K

RES: $10.84SUP: $2.03SMA50: $6.76SMA200: $9.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GTBP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GTBP Butterfly Map → + Track GTBP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GTBP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GTBP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GTBP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GTBP)

Health Care Rank #462 of 1016 ⚔️ CLRB vs GTBP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GTBP vs. CLRB, TVRD, ASBP, CALC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, GT Biopharma Inc. (GTBP) ranks #462 by composite RQD confidence (46/100, grade D) and #882 by equity capitalization ($11.5M). Within this direct 5-issuer industry benchmark cohort, GTBP leads on earnings valuation at N/A trailing P/E, while GTBP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CALC currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with GTBP at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GTBP ACTIVE GT Biopharma Inc.	D	46/100	—	—	-35.0%	+1.63%	$11.5M	Benchmark Subject
CLRB Cellectar Biosciences Inc.	D-	37/100	—	—	-35.0%	-1.61%	$11.5M	/clrb-vs-gtbp →
TVRD Tvardi Therapeutics Inc.	D-	40/100	—	—	-35.0%	-2.73%	$11.5M	/tvrd-vs-gtbp →
ASBP Aspire-Lakewood Holdings Inc.	E	33/100	—	-1.9%	-35.0%	-4.50%	$11.9M	/asbp-vs-gtbp →
CALC CalciMedica Inc.	D	47/100	—	—	-35.0%	+5.42%	$11.9M	/calc-vs-gtbp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000109657

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GT Biopharma Inc. (GTBP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$28.4M, operating cash flow of -$12.9M, and free cash flow of -$12.9M (-0.1% YoY). On the balance sheet, GTBP closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$28.4M	-$12.9M	-$12.9M	$8.1M	—
FY2024 (FY)	2024-12-31	$0	-$13.2M	-$12.9M	-$12.9M	$4.2M	—
FY2023 (FY)	2023-12-31	$0	-$7.6M	-$8.9M	-$8.9M	—	—

3. GTBP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GTBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, GT Biopharma Inc. (NASDAQ: GTBP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $5.60 (+1.63% 1D, market cap $11.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, GTBP ranks #462 in composite RQD confidence.

How does GTBP compare to CLRB and TVRD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GTBP carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLRB (Cellectar Biosciences Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $11.5M) and TVRD (Tvardi Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.5M). Among the 5-stock peer group, GTBP leads on earnings multiple (N/A) while GTBP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GTBP?

Per GTBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000109657), GT Biopharma Inc. generated $0 in revenue, -$28.4M in net income, and -$12.9M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GTBP trading relative to its 50-day, 200-day, and 52-week technical levels?

GTBP last traded at $5.60 (+1.63% on volume of 57,027 shares), positioning the stock -17.16% below its 50-day simple moving average ($6.76) and -42.56% below its 200-day simple moving average ($9.75). Across its 52-week range of $4.91 to $28.75, GTBP sits at the 2.9% percentile with a 14-day RSI of 41.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.90 to $6.30).